In addition to MYC, TSPX also represses MYB, an oncogenic transcription activator involved in the development of various malignant tumors including leukemia, colon cancer, and breast cancer, as well as prostate cancer [54–57]. Here, TSPYL2 is linked to colonic neoplasm.